Skip to content
Business Company News, Medical Health Aged Care

Professor Peter van Wijngaarden to become next Director and CEO of The Florey

The Florey 2 mins read

The Florey Board appoints new Director and CEO  

After an extensive global search, Professor Peter van Wijngaarden has been named as the next Director and CEO of The Florey Institute of Neuroscience and Mental Health. 

Board Chair Mr Martin Adams said Professor van Wijngaarden is an outstanding leader and an experienced clinician researcher who will take The Florey’s work to the world stage. 

“On behalf of the Board, I warmly welcome Peter to The Florey. As the largest brain research centre in the Southern Hemisphere, The Florey is home to remarkably talented people committed to advancing neuroscience and mental health research. Peter is exceptionally well-placed to take The Florey’s impact to the next level.” 

Professor van Wijngaarden said he was looking forward to taking up his new role next month. 

“I am honoured to be joining The Florey as its new Director and excited to be working with scientists who are leading the world in making fundamental discoveries in neuroscience and improving diagnostics and treatments for an impressive range of mental health and brain-related conditions,” Professor van Wijngaarden said.  

“The Florey has an incredible reputation and I look forward to building on that impressive legacy,” he said. 

Mr Adams thanked retiring Director Professor Trevor Kilpatrick for his leadership and commitment to the organisation.  

"Trevor has done an outstanding job leading The Florey through a period of important structural changes which have positioned us to continue to make significant scientific breakthroughs with our partners. I’m confident that Peter will build upon these efforts.”  

Professor Kilpatrick said he was proud to have served The Florey as its sixth Director. 

“I’m delighted that Professor van Wijngaarden has accepted this appointment,” Professor Kilpatrick said.  

“I have known Peter since his return from Cambridge where he undertook research in regenerative neuroscience with my long-term friend and colleague Professor Robin Franklin. 

“Since then, Peter has had a stellar career as a clinician scientist, administrator and entrepreneur. He is ideally placed to lead The Florey in the next phase of its journey as a world-leading neuroscience and mental health-oriented research institute.” 

Peter is Professor of Ophthalmology at the University of Melbourne and has served as Deputy Director at the Centre for Eye Research Australia (CERA). 

His research interests include retinal imaging, artificial intelligence, multiple sclerosis and Alzheimer’s disease. 

 


Key Facts:
  • Professor Peter van Wijngaarden has been selected to lead The Florey from 1 August 2024 

  • Professor van Wijngaarden is currently Deputy Director of the Centre for Eye Research Australia 


About us:

The Florey is Australia’s leading brain research institute with a focus on improving the lives of people with neurological and psychiatric conditions. The Florey’s research missions are centred around dementia, epilepsy, mental health and developing ways to protect and repair the brain. These missions are strengthened by The Florey’s expertise in neurotherapeutics, neuroimaging, synaptic biology and systems neuroscience. With 600 researchers, The Florey is the largest research centre of its kind in the southern hemisphere.

Find out more about us on our website: www.florey.edu.au


Contact details:

Kathryn Powley, Media and Communications Manager

kathryn.powley@florey.edu.au | 0456 666 271

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 17/02/2025
  • 15:07
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New ZealandGynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the…

  • Contains:
  • Business Company News, Oil Mining Resources
  • 17/02/2025
  • 11:59
New Age Exploration (ASX:NAE)

New Age Exploration Reports High-Grade Gold Results up to 15.6g/t at Wagyu Project, Central Pilbara, WA

HIGHLIGHTS Resampling of Phase 2 air core drilling confirms further significant gold intercepts at the Wagyu Gold Project in Central Pilbara, Western Australia Assay…

  • Contains:
  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.